scientific program Best of 18 th IASLC World Conference on Lung Cancer (WCLC) 2017 February Radisson Blu Park Hotel Athens Greece

Transcription

1 Best of 18 th IASLC World Conference on Lung Cancer (WCLC) 2017 ΕΡΕΥΝΗΤΙΚΟ & ΕΚΠΑΙΔΕΥΤΙΚΟ ΙΝΣΤΙΤΟΥΤΟ ΚΛΙΝΙΚΗΣ ΟΓΚΟΛΟΓΙΑΣ Με την Επιστημονική Συνεργασία της Ογκολογικής Κλινικής του Πανεπιστημιακού Νοσοκομείου Λάρισας της Ογκολογικής Μονάδας Γ Πανεπιστημιακής Κλινικής Νοσοκομείου Σωτηρία της Ελληνικής Ογκολογικής Ερευνητικής ομάδας (Ε.Ο.Ε.Ο.) Licensed by INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER Conquering Thorasic Cancers Worldwide February Radisson Blu Park Hotel Athens Greece scientific program Scientific Cultural Events and Publications T F E info@scep.gr

2 Registration FEBRUARY 23 th : CLINICAL TRIALS Chairs: Β. Γεωργούλιας, Δ. Τραφαλής Presenter: Η. Κοττέας (15 min) MA ENROLLMENT OF MINORITIES, THE ELDERLY, AND WOMEN IN LUNG CANCER CLINICAL TRIALS MA QUALITY OF DATA INFORMING EPIDEMIOLOGICAL STUDIES IN PATIENTS WITH LUNG CANCER OA RETHINKING PROGRESSION-FREE SURVIVAL (PFS) AS A CLINICAL TRIALS SURROGATE FOR OVERALL SURVIVAL (OS) OA PHASE 2 BASKET TRIAL OF ADO-TRASTUZUMAB EMTANSINE IN PATIENTS WITH HER2 MUTANT OR AMPLIFIED LUNG CANCERS Discussant: Α. Χαρπίδου (10 min) Q & Α 12: EPIDEMIOLOGY AND PREVENTION OF LUNG CANCER Chairs: E. Ζαχαριάδης, Α. Τσαρουχά Presenter 1: M. Ζωντανός (20 min) PL CURRENT STATUS OF SMOKING CESESSION PROGRAM (TOBACCO CONTROL) OA COSTS AND COST-EFFECTIVENESS OF SMOKING CESSATION WITHIN AN ORGANIZED CT LUNG CANCER (LC) SCREENING PROGRAM OA SOCIOECONOMIC FACTORS AFFECTING OUTCOMES IN NON-SMALL CELL LUNG CANCER (NSCLC): A LARGE POPULATION BASED ANALYSIS Presenter 2: N. Μποσταντζόγλου (15 min) OA FINAL REPORT OF THE INHERIT EGFR STUDY - 33 UNRELATED KINDREDS CARRYING GERMLINE EGFR MUTATIONS OA SURVIVAL TRENDS AMONG NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS OVER A DECADE: IMPACT OF INITIAL THERAPY AT ACADEMIC CENTERS MA CLINICAL PROGNOSTIC MODEL FOR OLDER PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER Discussion: Γ. Κρομμύδας (15 min) EDUCATIONAL SESSION NEW NSCLC STAGING Chairs: Α. Ράπτη, Λ. Θάνος Presenter: I. Βαμβακάρης (25 min) PL THE IASLC LUNG CANCER STAGING PROJECT: ANALYSIS OF RESECTION MARGIN STATUS AND PROPOSALS FOR R STATUS DESCRIPTORS FOR NON-SMALL CELL LUNG CANCER

3 ES NEW TNM CLASSIFICATION Discussion: I. Γκιόζος (15 min) Coffee break 15:00-15:45 EARLY STAGE AND LOCALLY ADVANCED NSCLC Chairs: Κ. Ηλιάδης, Η. Καΐνης Part I Presenter: K. Βάχλας (10 min) OA FEASIBILITY OF PULMONARY RESECTION FOLLOWING DEFINITIVE CHEMORADIOTHERAPY FOR PRIMARY LUNG CARCINOMA OA PRIMARY TUMOR RESECTION VERSUS MAINTENANCE THERAPY FOR PATIENTS WITH OLIGOMETASTATIC NON-SMALL CELL LUNG CANCER MA THE VALIDITY OF TNM CLASSIFICATION AFTER INDUCTION TREATMENT IN PATIENTS WITH NSCLC: PULMONARY RESECTION WITH OR WITHOUT INDUCTION TREATMENT Discussion: Χ. Πανόπουλος (5 min) Part II Presenter: Λ. Τουφεξιάν (15 min) OA RISK OF RECURRENCE IN STAGE I ADENOCARCINOMA OF THE LUNG: A MULTI-INSTITUTIONAL STUDY ON INTERACTION WITH TYPE OF SURGERY AND TYPE OF NODAL STAGING OA RECURRENCES AND 2ND PRIMARY CANCERS IN THE IFCT TRIAL ASSESSING A CT-SCAN-BASED FOLLOW-UP AFTER LUNG CANCER SURGERY OA SURGEON PRACTICES FOR POST RESECTION LUNG CANCER SURVEILLANCE: COMPARISONS OF STS AND ESTS MEMBERS Discussion: Κ. Ηλιάδης (5 min) 15:45-16:15 SATELLITE LECTURE EDUCATIONAL SESSION Chair: A. Κωτσάκης, Λ. Τουφεξιάν Presenter: Λ. Ζέλλος (25 min) ES MINIMALLY INVASIVE SURGERY FOR LUNG CANCER, INCLUDING ROBOTICS 16: DIAGNOSTIC RADIOLOGY, STAGING AND SCREENING FOR LUNG CANCER Chairs: Γ. Τσουκαλάς, Μ. Βασλαματζής Presenter: Σ. Τσαγκούλη (20 min) PL MAJOR ADVANCES IN CT SCREENING: A RADIOLOGIST S PERSPECTIVE OA LUNG CANCER SCREENING: PARTICIPANT SELECTION BY RISK MODEL THE PAN-CANADIAN STUDY 03

4 OA BENEFITS, HARMS, AND ECONOMIC EFFICIENCY OF LOW-DOSE CT LUNG CANCER SCREENING STRATEGIES IN A POPULATION-BASED SETTING Comment: Κ. Ταβερναράκη (10 min) Q & Α Presenter: Σ. Τσιμπούκης (10 min) OA GENE-BASED RISK STRATIFICATION OF NLST-ACRIN SCREENING PARTICIPANTS IDENTIFIES THE SWEET SPOT OF SCREENING (N=10,054) OA THOROUGHNESS OF STAGING AND THE OUTCOMES OF SURGICAL RESECTION OUTCOMES IN POTENTIALLY CURABLE NONSMALL CELL LUNG CANCER (NSCLC) Comment: M. Βασλαματζής (5 min) 17:05-17:30 Coffee break 17:30-18:30 TREATMENT ADVANCES IN SCLC Chairs: N. Βαρδάκης, A. Καραμπεάζης Presenter 1: K. Ράπτη (15 min) OA NEXT GENERATION SEQUENCING OF LARGE-CELL NEUROENDOCRINE CARCINOMA REVEALS AN ASSOCIATION OF PIK3CA MUTATIONS WITH BRAIN METASTASES OA THE CORRELATION OF DLL3 EXPRESSION WITH HIGH-GRADE PULMONARY NEUROENDOCRINE CARCINOMA CLINICOPATHOLOGIC FEATURES AND PROGNOSES OA MAJOR DRIVERS OF CHEMOTHERAPY AND RADIATION UTILIZATION FOR LIMITED-STAGE SMALL CELL LUNG CANCER IN THE UNITED STATES Presenter 2: N. Δεσσές (15 min) OA EXPLORATORY ANALYSIS FOR PREDICTORS OF BENEFIT OF PARP INHIBITOR THERAPY IN EXTENSIVE STAGE SMALL CELL LUNG CANCER: ECOG-ACRIN 2511 STUDY OA PAZOPANIB MAINTENANCE FOR EXTENSIVE DISEASE SMALL CELL LUNG CANCER: A RANDOMIZED, PLACEBOCONTROLLED PHASE II STUDY (KCSG-LU12-07) Discussion: E. Κοντοπόδης (15 min) 18: EGFR TARGETED THERAPIES Chairs: Γ. Κουμάκης, N. Κεντεποζίδης Presenter 1: T. Μπηλίδας (15 min) OA FIRST-LINE DACOMITINIB VERSUS GEFITINIB IN ADVANCED NON-SMALL -CELL LUNG CANCER WITH EGFR MUTATION SUBGROUPS OA OSIMERTINIB VS SOC EGFR-TKI AS FIRST-LINE TREATMENT IN PATIENTS WITH EGFRM ADVANCED NSCLC (FLAURA): PLASMA CtDNA ANALYSIS OA SERIAL BIOPSIES IN PATIENTS WITH EGFR-MUTANT NSCLC HIGHLIGHT THE SPATIAL AND TEMPORAL HETEROGENEITY OF RESISTANCE MECHANISMS 04

5 MA GENOMIC PROFILING OF EGFR T790M MUTATED NONSMALL CELL LUNG CANCER TO EVALUATE THE MECHANISMS OF RESISTANCE TO OSIMERTINIB Presenter 2: Ι. Κωτσαντής (15 min) OA CHARACTERIZING THE GENOMIC LANDSCAPE OF EGFR C797S IN LUNG CANCER USING CtDNA NEXT-GENERATION SEQUENCING OA OSIMERTINIB RESISTANCE MEDIATED BY LOSS OF EGFR T790M IS ASSOCIATED WITH EARLY RESISTANCE AND COMPETING RESISTANCE MECHANISMS OA IDENTIFICATION OF NOVEL POTENTIALLY TARGETABLE GENOMIC ALTERATIONS IN PAIRED TUMORS WITH ACQUIRED EGFR TKI RESISTANCE BY NGS MA THE ALTERATION OF T790M PREVALENCE BETWEEN 19 DELETIONS AND L858R IN NSCLC AFTER EGFR-TKIS THERAPY, A META-ANALYSIS Presenter 3: Π. Κατσαούνης (15 min) OA TATTON PH IB EXPANSION COHORT: OSIMERTINIB PLUS SAVOLITINIB FOR PTS WITH EGFR-MUTANT MET-AMPLIFIED NSCLC AFTER PROGRESSION ON PRIOR EGFR-TKI OA CLONALITY OF C-MET COPY NUMBER GAIN AS A DETERMINANT OF PRIMARY TKI RESISTANCE IN EGFR-MUTANT NSCLC OA EFFICACY AND SAFETY OF ERLOTINIB VS VINORELBINE/ CISPLATIN AS ADJUVANT THERAPY FOR STAGE IIIA EGFR MUTANT NSCLC PATIENTS MA PHASE I/II STUDY OF S49076, A MET/AXL/FGFR INHIBITOR, COMBINED WITH GEFITINIB IN NSCLC PATIENTS PROGRESSING ON EGFR TKI Discussion: A. Αργύρης (15 min) :30 EDUCATIONAL SESSION Chairs: Χ. Κουρούσης, Α. Κωτσάκης Presenter: Ν. Κεντεποζίδης ES RESISTANCE MECHANISMS IN TKI 05

6 FEBRUARY 24 th :00-11:00 PROGNOSTIC & PREDICTIVE BIOMARKERS Chairs: K. Συρίγος, I. Μούντζιος Presenter 1: K. Τσαπακίδης (20 min) OA CHARACTERISTICS OF LUNG CANCER CELL-FREE TUMOR DNA (CfDNA) SHEDDING AND CORRELATION WITH TUMOR BURDEN AS MEASURED BY RECIST OA CIRCULATING TUMOR DNA MUTANT ALLELE FREQUENCY AND TUMOR BURDEN AS BIOMARKERS FOR RESPONSE TO IMMUNE CHECKPOINT BLOCKADE OA INNATE GENETIC EVOLUTION OF LUNG CANCERS AND SPATIAL HETEROGENEITY: ANALYSIS OF TREATMENT-NAÏVE LESIONS OA CLINICAL POTENTIAL OF SPUTUM IN DETECTING DRIVER MUTATIONS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER: A PRELIMINARY STUDY Discussion: Γ. Καλλέργη (15 min) Presenter 2: Α. Ζώη (20 min) OA DETECTION OF EGFR MUTATIONS FROM PLASMA CTDNA IN THE OSIMERTINIB PHASE III TRIAL (AURA3): COMPARISON OF THREE PLASMA ASSAYS OA UNIQUE GENETIC PROFILES FROM CIRCULATING CELLFREE DNA OF CEREBROSPINAL FLUID IN LEPTOMENINGEAL METASTASES OF EGFR MUTANT NSCLC OA LIQUID BIOPSY IN THE LUNG CANCER CLINIC: A PROSPECTIVE STUDY OF PLASMA DNA NEXT GENERATION SEQUENCING TO GUIDE MATCHED THERAPY OA LONGITUDINAL MUTATION MONITORING IN PLASMA BY DEEP SEQUENCING AS A POTENTIAL PREDICTOR OF DISEASE PROGRESSION IN NSCLC Discussion: Φ. Παπαγεωργίου (15 min) Presenter 3: M. Παρασκευά (10 min) OA GENOMIC PROFILE OF CELL-FREE DNA FROM SPUTUM, PLASMA, URINE AND TUMOR TISSUE AND CORRELATION WITH CLINICAL EFFECT IN ADVANCED NSCLC OA WHOLE GENOME TUMOR-NORMAL SEQUENCING REVEALS POTENTIAL FALSE POSITIVES VERSUS STANDARD CGP SEQUENCING IN PATIENTS WITH NSCLC Presenter 4: M. Ροβίθη (10 min) MA THE POTENTIAL OF CtDNA SEQUENCING IN DISEASE MONITORING AND DEPICTING GENOMIC EVOLUTION OF SMALL-CELL LUNG CANCER UNDER THERAPY MA LIQUID BIOPSIES FOR MONITORING BRAF MUTATION (V600E) IN ANDVANCED BRAF (V600E) NON-SMALL CELL LUNG CANCER (NSCLC) MA NGS SEQUENCING BASED LIQUID / TISSUE BIOPSY IDENTIFIED COEXISTENCE OF HER2 AMPLIFICATION AND MUTATION IN ADVANCED NSCLC PATIENTS 06 Discussion: A. Βουτσινά (15 min)

7 11:00-11:15 Coffee break 11:15-12:15 THE NEW ASPECT OF RADIATION THERAPY Chairs: E. Μαραγκουδάκης, I. Βρούβας Presenter 1: Α. Στεργιούλα (15 min) OA STEREOTACTIC RADIOTHERAPY AS SALVAGE TREATMENT AFTER SURGERY AND CURATIVE INTENDED RADIOTHERAPY FOR PATIENTS WITH NSCLC OA ANALYSIS OF RADIOTHERAPY QUALITY ASSURANCE DATA FOR THE CONVERT TRIAL - DOES NON-COMPLIANCE TO PROTOCOL AFFECT SURVIVAL? OA RADIATION THERAPY IS ASSOCIATED WITH AN INCREASED INCIDENCE OF CARDIAC EVENTS IN SMALL CELL LUNG CANCER PATIENTS Presenter 2: Γ. Φιλίππου (15 min) OA TRACKING MAJOR SYMPTOM BURDEN FROM CHEMOTHERAPY CONCURRENT WITH 3D VS. IMRT VS. PROTON BEAM RADIOTHERAPY FOR NSCLC OA STEREOTACTIC ABLATIVE RADIOTHERAPY VERSUS SURGERY IN EARLY LUNG CANCER: A META-ANALYSIS OF PROPENSITY SCORE-ADJUSTED STUDIES MA A PROPENSITY-MATCHED ANALYSIS OF LOBECTOMY AND STEREOTACTIC BODY RADIOTHERAPY FOR EARLY STAGE NONSMALL CELL LUNG CANCER MA PULMONARY OLIGOMETASTASES TREATED BY STEREOTACTIC BODY RADIATION THERAPY (SBRT): A NATIONWIDE SURVEY OF 1,378 PATIENTS Discussion: Ε. Μπερούκας (15 min) 12:15-13:15 ALK, HER-2 AND ROS REARRANGED ADVANCED/METASTATIC NSCLC Chairs: Χ. Παπαδημητρίου, Λ. Βαμβακάς Presenter 1: Γ. Ιωαννίδης (15 min) OA BRIGATINIB IN CRIZOTINIB-REFRACTORY ALK+ NSCLC: UPDATED EFFICACY AND SAFETY RESULTS FROM ALTA, A RANDOMIZED PHASE 2 TRIAL OA PHASE 2 STUDY OF LORLATINIB IN PATIENTS WITH ADVANCED ALK+ /ROS1+ NON-SMALL-CELL LUNG CANCER MA CLINICAL IMPLICATIONS OF ALK RESISTANCE MUTATIONS: INSTITUTIONAL EXPERIENCE AND LAUNCH OF REMOTE PARTICIPATION STUDY MA ALK/ROS1/TRK INHIBITOR TPX-0005 EFFECTIVELY OVERCOMES CLINICAL RESISTANCE SOLVENT FRONT MUTATIONS Presenter 2: E. Λιανός (15 min) OA EFFICACY AND UPDATED SAFETY OF CERITINIB (450 MG OR 600 MG) WITH LOW-FAT MEAL VS 750 MG FASTED IN ALK+ METASTATIC NSCLC OA FINAL RESULT OF PHASE I/II STUDY (AF-001JP) OF ALECTINIB, A SELECTIVE CNS-ACTIVE ALK INHIBITOR, IN ALK+ NSCLC PATIENTS (PTS) MA PATIENTS WITH ALK IHC-POSITIVE/FISH-NEGATIVE NSCLC BENEFIT FROM ALK TKI TREATMENT: RESPONSE DATA FROM THE GLOBAL ALEX TRIAL 07

8 Presenter 3: Δ. Νάση MA A PHASE II STUDY OF TRASTUZUMAB EMTANSINE IN HER2-POSITIVE NON-SMALL-CELL-LUNG CANCER MA SHORT-TERM CULTURE OF PATIENT DERIVED TUMOR ORGANOIDS IDENTIFY NERATINIB/TRASTUZUMAB AS AN EFFECTIVE COMBINATION IN HER2 MUTANT LUNG CANCER Discussion: Μ. Μπακογεώργος (15 min) 13:15-14:00 EMERGING GENOMIC TARGETS Chairs: Ι. Δροσίτης, Γ. Ιωαννίδης Presenter: Β. Ραμφίδης (25 min) OA THE PRECLINICAL AND CLINICAL ACTIVITY OF POZIOTINIB, A POTENT, SELECTIVE INHIBITOR OF EGFR EXON 20 MUTANT NSCLC OA FINAL RESULTS OF A PHASE 2 STUDY OF THE HSP90 INHIBITOR LUMINESPIB (AUY922) IN NSCLC PATIENTS HARBORING EGFR EXON 20 INSERTIONS OA SPECTRUM OF 1,014 SOMATIC BRAF ALTERATIONS DETECTED IN CELL-FREE DNA OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER OA PLASMA GENOMIC PROFILING AND OUTCOMES OF PATIENTS WITH MET EXON 14-ALTERED NSCLCS TREATED WITH CRIZOTINIB ON PROFILE 1001 OA GENOMIC ANALYSIS OF NON-SMALL CELL LUNG CANCER (NSCLC) CASES WITH FOCAL AND NON-FOCAL MET AMPLIFICATION Discussion: Β. Ραμφίδης (10 min) 14:00-15:00 Light Lunch 15:00-15:55 NOVEL TARGETS AND BIOMARKERS IN MALIGNANT PLEURAL MESOTHELIOMA AND THYMOMAS Chairs: E. Σαμαντάς, E. Κοντοπόδης Presenter 1: J. Duran-Moreno (15 min) OA IPILIMUMAB AND NIVOLUMAB IN THE TREATMENT OF RECURRENT MALIGNANT PLEURAL MESOTHELIOMA: A PHASE II STUDY MA A PHASE II STUDY OF NIVOLUMAB: A MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY IN MALIGNANT PLEURAL MESOTHELIOMA (MERIT) MA TREMELIMUMAB PLUS DURVALUMAB IN FIRST- OR SECOND-LINE MESOTHELIOMA PATIENTS: FINAL ANALYSIS OF THE NIBIT-MESO-1 STUDY MA NINTEDANIB + PEMETREXED/CISPLATIN IN MALIGNANT PLEURAL MESOTHELIOMA (MPM): PHASE II BIOMARKER DATA FROM THE LUMEMESO STUDY Presenter 2: K. Τσιγαρίδας (15 min) 08 OA PROPHYLACTIC IRRADIATION OF TRACTS (PIT) IN PATIENTS WITH PLEURAL MESOTHELIOMA: RESULTS OF A MULTICENTRE PHASE III TRIAL

9 OA RADIOIMMUNOTHERAPY COMBINING CTLA-4 BLOCKADE OR LOW-DOSE CYCLOPHOSPHAMIDE WITH LOCAL RADIATION IN MURINE MALIGNANT MESOTHELIOMA OA A PHASE II STUDY OF PEMBROLIZUMAB FOR PATIENTS WITH REFRACTORY OR RELAPSED THYMIC EPITHELIAL TUMOR MA DIFFERENT PATTERN AND PROGNOSTIC ROLE OF PD-L1, IDO, AND FOXP3 TREG EXPRESSION IN THYMOMA AND THYMIC CARCINOMA Discussion: Π. Κατσαούνης (15 min) 15:55-16:50 IMMUNO-BIOLOGY Chairs: Π. Κορκολοπούλου, Ε. Πατσέα Presenter: L. Abou-Assabeh (30 min) PL BLUEPRINT 2: PD-L1 IMMUNOHISTOCHEMISTRY COMPARABILITY STUDY IN REAL-LIFE, CLINICAL SAMPLES OA DISTRIBUTION OF PD-L1 TUMOR EXPRESSION BY ASSAY TYPE IN PATIENTS WITH METASTATIC NSCLC (MNSCLC) OA IMMUNE, MOLECULAR AND T CELL REPERTOIRE LANDSCAPE OF 235 RESECTED NON-SMALL CELL LUNG CANCERS AND PAIRED NORMAL LUNG TISSUES OA CO-EXPRESSION OF IDO1 AND PD-L1 INDICATES MORE AGGRESSIVE FEATURES OF LUNG ADENOCARCINOMA OA CONTRACTION OF T CELL CLONALITY IN LUNG CANCER METASTASES Discussion: A. Κουτσόπουλος (15 min) 16:50-17:15 Coffee break 17:15-18:15 IMMUNOTHERAPY CHECKPOINT INHIBITORS IN ADVANCED NSCLC (I) Chairs: Β. Γεωργούλιας, M. Τσιατάς Presenter 1: N. Τσουκαλάς (20 min) PL CURRENT STATUS AND FUTURE OF IMMUNOTHERAPY IN LUNG CANCER PL PATIENT-REPORTED OUTCOMES WITH DURVALUMAB AFTER CHEMORADIATION IN LOCALLY ADVANCED, UNRESECTABLE NSCLC: DATA FROM PACIFIC MA A PHASE II STUDY OF PEMBROLIZUMAB IN EGFR MUTANT, PD-L1+, TYROSINE KINASE INHIBITOR (TKI) NAÏVE PATIENTS WITH ADVANCED NSCLC MA ELDERLY LUNG CANCER PATIENTS ON IMMUNOTHERAPY: PRELIMINARY RESULTS FROM THE ELDERS STUDY Presenter 2: E. Ελευθεράκης (20 min) OA UPDATED EFFICACY RESULTS FROM THE BIRCH STUDY: FIRST-LINE ATEZOLIZUMAB THERAPY IN PD-L1 SELECTED PATIENTS WITH ADVANCED NSCLC OA IFCT-1502 CLINIVO: REAL-LIFE EXPERIENCE WITH NIVOLUMAB IN 600 PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER NSCLC 09

10 OA UPDATED ANALYSIS OF KEYNOTE-024: PEMBROLIZUMAB VS PLATINUM-BASED CHEMOTHERAPY FOR ADVANCED NSCLC WITH PD-L1 TPS 50% OA PHASE II STUDY OF PEMBROLIZUMAB FOR OLIGOMETASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) FOLLOWING COMPLETION OF LOCALLY ABLATIVE THERAPY (LAT) Discussion: Γ. Οικονομόπουλος (15 min) 18:15-19:10 IMMUNOTHERAPY CHECKPOINT INHIBITORS IN ADVANCED NSCLC (II) Chairs: Κ.Ν. Μπαξεβάνης, A. Κωτσάκης Presenter 1: Ε. Κοντοπόδης (15 min) OA PEMETREXED-CARBOPLATIN PLUS PEMBROLIZUMAB AS FIRST-LINE THERAPY FOR ADVANCED NONSQUAMOUS NSCLC: KEYNOTE-021 COHORT G UPDATE OA FIRST-LINE NIVOLUMAB PLUS PLATINUM-BASED DOUBLET CHEMOTHERAPY FOR ADVANCED NSCLC: CHECKMATE YEAR UPDATE MA NIVOLUMAB IN ADVANCED NON-SQUAMOUS NSCLC PATIENTS WITH KRAS MUTATIONS: RESULTS FROM THE ITALIAN EXPANDED ACCESS PROGRAM (EAP) MA REAL-WORLD RESULTS IN NON-SQUAMOUS NON-SMALL CELL LUNG CANCER PATIENTS: ITALIAN NIVOLUMAB EXPANDED ACCESS PROGRAMME Presenter 2: Β. Παπαδόπουλος (15 min) MA THE COST AND THE BENEFIT: FRONT-LINE IMMUNOTHERAPY FOR NON-SMALL CELL LUNG CANCER MA DURVALUMAB ± TREMELIMUMAB WITH PLATINUM DOUBLETS IN NON-SMALL CELL LUNG CANCER: CANADIAN CANCER TRIALS GROUP STUDY IND.226 MA NAB-PACLITAXEL + DURVALUMAB AS SECOND- OR THIRD-LINE TREATMENT OF ADVANCED NSCLC: RESULTS FROM ABOUND.2L+ MA HYPERPROGRESSIVE DISEASE (HPD) IS FREQUENT IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS (PTS) TREATED WITH ANTI PD1/PD-L1 AGENTS (IO) MA PHASE 2 STUDY OF PEMBROLIZUMAB PLUS CC-486 VS PEMBROLIZUMAB PLUS PLACEBO IN PREVIOUSLY TREATED PATIENTS WITH ADVANCED NSCLC Discussion: Ν. Πισταμαλτζιάν (15 min) 19:10-19:30 Closing Remarks 10

11 Scientific Cultural Events and Publications T F E info@scep.gr